ENGLAND - A non-hormonal drug, fezolinetant (marketed as Veoza), is now accessible on the NHS in England. This medication offers an alternative for women experiencing menopausal hot flushes and night sweats, particularly those for whom Hormone Replacement Therapy (HRT) is unsuitable or a preference against it. The approval signifies a new avenue for managing these disruptive symptoms for an estimated half a million women.
This new treatment targets women who cannot take HRT due to medical reasons, such as a history of deep vein thrombosis or pulmonary embolism. It also serves as an option for those who simply prefer a non-hormonal approach. Healthcare professionals highlight the significant impact hot flushes and night sweats can have on a woman's quality of life, affecting sleep, fatigue, and overall well-being.
The drug works by addressing the hormonal shifts, specifically falling estrogen levels, which impact the brain and can lead to various menopausal symptoms. While HRT is considered the most effective treatment for those who can use it, the availability of fezolinetant provides a much-needed alternative. Initial considerations for prescribing the drug involve a blood test to assess liver function.
Read More: Abortion Pill Access Faces New Legal Challenges
A Growing Need for Alternatives
For decades, treatment options for menopausal symptoms have been limited, despite the vast number of women affected. The introduction of fezolinetant addresses this gap, offering a new line of treatment beyond traditional HRT. Reports indicate that over 500,000 women in England are now eligible to benefit from this new medication.
The impact of menopausal symptoms extends beyond physical discomfort, influencing productivity, exercise, and emotional states. By providing a non-hormonal option, the NHS aims to improve the daily lives of women navigating this life stage. The long-term effects and benefits for women who cannot use HRT are still under observation, with no prior data available on such cases.
